Novartis AG Sells Stake in Indian Unit

Novartis AG has agreed to sell its entire 70.68% stake in Novartis India Limited, comprising 1,74,50,680 equity shares.

Deal Execution Details

Novartis AG has signed an agreement to sell its full 70.68% stake, or 1,74,50,680 shares, in Novartis India Limited. The deal was executed on February 19, 2026, with WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners acquiring the shares. Novartis AG confirmed on March 31, 2026, that these shares are free of any encumbrances. This information was disclosed on April 7, 2026.

Strategic Significance

This deal marks a key strategic shift for Novartis AG, signaling its intent to focus on innovative medicines and streamline its global operations. The divestment from its listed Indian commercial arm allows the parent company to exit a business focused on established and off-patent drugs. It will retain its core innovative medicine portfolio and R&D presence in India through its wholly-owned subsidiary, Novartis Healthcare Private Limited (NHPL).

Strategic Context

Novartis AG's decision to sell its stake in Novartis India Limited followed a strategic review in February 2024. The parent company has been globally repositioning as a "pure-play innovative medicines" company. Novartis India Limited primarily deals with older, off-patent drugs in areas such as immunology, neuroscience, and pain management. In contrast, Novartis Healthcare Private Limited (NHPL) will continue to house the company's innovative commercial operations, R&D teams, and corporate centre in Hyderabad, aligning with Novartis's global strategy. The deal is valued at approximately ₹1,446 crore, with an additional mandatory open offer extended to public shareholders for up to 26% of the company's equity.

Implications for Stakeholders

• Shareholders of Novartis India Ltd will have an opportunity to exit their investment through the stake sale by Novartis AG and the subsequent open offer by the acquiring consortium.
• The company's operational direction and strategy will likely evolve under the new ownership of WaveRise Investments, ChrysCapital, and Two Infinity Partners.
• Novartis AG will no longer hold a controlling stake in the listed Indian entity, signifying a clear separation from its legacy product business in the country.
• Novartis Healthcare Private Limited (NHPL), the parent’s wholly-owned subsidiary, will continue to operate independently, focusing on innovative medicines and R&D.

Potential Risks

• The strategic vision and execution capabilities of the new private equity owners in managing the legacy product portfolio of Novartis India Ltd.
• Potential changes in market dynamics for established generics and branded generics under new management.

Competitive Landscape

Novartis India Ltd operates in a competitive landscape alongside major Indian pharmaceutical players. Its key competitors include Sun Pharmaceutical Industries, Zydus Lifesciences, Abbott India, and Pfizer Ltd. The divestment might alter Novartis India's competitive positioning as it transitions to new ownership, potentially focusing more keenly on its established product strengths.

Recent Financials

• For the year ended December 31, 2024, Novartis India reported total revenue of ₹257.33 crore and a net profit of ₹2.09 crore.
• In the previous year, ended December 31, 2023, revenue was ₹228.82 crore and net profit stood at ₹1.56 crore.

Key Next Steps

• The successful conclusion of the open offer and the final ownership structure post-acquisition.
• The strategic plans and future growth trajectory for Novartis India Ltd under its new private equity owners.
• Any potential changes in the company's business model or product focus.
• The market performance and stock movement of Novartis India Ltd following the change in control.
• The continued strategic focus of Novartis AG on its innovative medicines portfolio within India through NHPL.